A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

Status:
Completed

Trial end date:
2019-08-26

Target enrollment:

Participant gender:

A Phase 1 double-blind, placebo-controlled, randomized single ascending dose incorporating an open-label, 2-period crossover, food effect cohort.

Phase 1

Centrexion Therapeutics